Romaniuk, W., Bolkun, L., Kalita, J., Galar, M., Bernatowicz, M., Ostrowska, H., & Kloczko, J. (2018). High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS. Ann Hematol.

Romaniuk, Wioletta, Lukasz Bolkun, Joanna Kalita, Marzenna Galar, Malgorzata Bernatowicz, Halina Ostrowska, a Janusz Kloczko. "High Chymotrypsin-like Activity in the Plasma of Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib Is Predictive of a Better Response and Longer PFS." Ann Hematol 2018.

Romaniuk, Wioletta, et al. "High Chymotrypsin-like Activity in the Plasma of Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib Is Predictive of a Better Response and Longer PFS." Ann Hematol 2018.